Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma

Journal of Clinical Investigation

Volumn 121, Issue 12, 2011, Pages 4838-4849

  Curiel Lewandrowski, Clara ^a,b   Yamasaki, Hisato ^c   Si, Chuan Ping ^c   Jin, Xiaoyi ^c   Zhang, Yujun ^c   Richmond, Jillian ^c   Tuzova, Marina ^c   Wilson, Kevin ^c   Sullivan, Beth ^d   Jones, David ^e   Ryzhenko, Nataliya ^c   Little, Frederick ^c   Kupper, Thomas S ^e   Center, David M ^c   Cruikshank, William W ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DENILEUKIN DIFTITOX; FLUOCINONIDE; HEAT SHOCK COGNATE PROTEIN 70; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; METHOTREXATE; PDZ PROTEIN; PREDNISONE; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; VORINOSTAT;

5' UNTRANSLATED REGION; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4 CD8 RATIO; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL ISOLATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; MALE; NUCLEAR LOCALIZATION SIGNAL; PDZ DOMAIN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PUVA; REGULATORY MECHANISM; RNA INTERFERENCE; SEQUENCE ANALYSIS; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSC70 HEAT-SHOCK PROTEINS; HUMANS; INTERLEUKIN-16; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; S-PHASE KINASE-ASSOCIATED PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, PROTEIN; SEQUENCE HOMOLOGY, AMINO ACID; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 84055193628     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI41769     Document Type: Article

References (64)

1. Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2008;22(5):979-996.
2. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet. 2008;371(9616):945-957.
3. McCann SA. Cutaneous T-cell lymphoma: overview and nursing perspectives. Nurs Clin North Am. 2007;42(3):421-455.
4. Foss F. Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol. 2004;16(5):421-428.
5. Klemke CD, et al. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res. 2009;69(10):4175-4183.
6. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol. 2009;129(5):1165-1173.
7. Contassot E, et al. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood. 2008;111(9):4780-4787.
8. Marzec M, et al. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood. 2008;111(4):2181-2189. (Pubitemid 351451532)
9. Dobbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/ paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998;92(1):252-258. (Pubitemid 28303200)
10. Yamanaka K, et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood. 2006;107(6):2440-2445. (Pubitemid 43345565)
11. Qin JZ, Kamarashev J, Zhang CL, Dummer R, Burg G, Dobbeling U. Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol. 2001;117(3):583-589. (Pubitemid 32955584)
12. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin- 15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood. 2001;98(9):2778-2783.
13. Asadullah K, et al. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol. 2000;9(4):248-251. (Pubitemid 30458506)
14. Yamanaka K, et al. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res. 2006;12(2):376-382. (Pubitemid 43166124)
15. Lee M, et al. Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins. Cancer Immunol Immunother. 2007;56(6):783-795. (Pubitemid 46723586)
16. Chupp GL, et al. Tissue and T cell distribution of precursor and mature IL-16. J Immunol. 1998; 161(6):3114-3119. (Pubitemid 28425739)
17. Ren F, et al. Pro-IL-16 regulation in activated murine CD4+ lymphocytes. J Immunol. 2005; 174(5):2738-2745. (Pubitemid 40279689)
18. Center DM, Cruikshank WW, Zhang Y. Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription. J Immunol. 2004;172(3):1654-1660. (Pubitemid 38116813)
19. Wilson KC, Cruikshank WW, Center DM, Zhang Y. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry. 2002;41(48):14306-14312. (Pubitemid 35403351)
20. Zhang Y, Kornfeld H, Cruikshank WW, Kim S, Reardon CC, Center DM. Nuclear translocation of the N-terminal prodomain of interleukin-16. J Biol Chem. 2001;276(2):1299-1303. (Pubitemid 32096559)
21. Cruikshank W, Little F. lnterleukin-16: the ins and outs of regulating T-cell activation. Crit Rev Immunol. 2008;28(6):467-483.
22. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol. 2003;171(10):4965-4968. (Pubitemid 37432773)
23. Cruikshank WW, Kornfeld H, Center DM. Signaling and functional properties of interleukin-16. Int Rev Immunol. 1998;16(5-6):523-540. (Pubitemid 28286183)
24. Zhang XM, Xu YH. The associated regulators and signal pathway in rIL-16/CD4 mediated growth regulation in Jurkat cells. Cell Res. 2002;12(5-6):363-372. (Pubitemid 135708348)
25. Zhang Y, et al. Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem. 1998;273(2):1144-1149. (Pubitemid 28049215)
26. Zhang Y, Tuzova M, Xiao ZX, Cruikshank WW, Center DM. Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP. J Immunol. 2008;180(1):402-408.
27. Furuhata A, et al. p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochem Biophys Res Commun. 2009;383(4):411-416.
28. Sabile A, et al. Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. Mol Cell Biol. 2006;26(16):5994-6004. (Pubitemid 44204519)
29. Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, Reuss-Borst M. Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol. 2001;28(1):12-21. (Pubitemid 32062019)
30. Richmond J, et al. Interleukin-16 as a marker of Sézary syndrome onset and stage. J Clin Immunol. 2011;31(1):39-50.
31. Lwin T, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantlecell and other non-Hodgkin B-cell lymphomas. Blood. 2007;110(5):1631-1638. (Pubitemid 47443981)
32. Wolowiec D, et al. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease. Eur J Haematol. 2009;82(4):260-266.
33. Appleman LJ, Chernova I, Li L, Boussiotis VA. CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation. Cell Cycle. 2006; 5(18):2123-2129. (Pubitemid 44553747)
34. Guo D, et al. Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk Res. 2009;33(5):678-685.
35. Scott SA, et al. Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. Leuk Res. 2004;28(12):1293-1301. (Pubitemid 39314409)
36. Wilson KC, et al. Regulation of nuclear Prointerleukin- 16 and p27(Kip1) in primary human T lymphocytes. Cell Immunol. 2005;237(1):17-27. (Pubitemid 41821078)
37. Muhlhahn P, et al. Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat Struct Biol. 1998;5(8):682-686. (Pubitemid 28359802)
38. Wilson KC, Center DM, Cruikshank WW, Zhang Y. Binding of HTLV-1 tax oncoprotein to the precursor of interleukin-16, a T cell PDZ domain-containing protein. Virology. 2003;306(1):60-67. (Pubitemid 36293396)
39. Pierson DM, et al. Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens. Cytometry B Clin Cytom. 2008;74(6):341-348.
40. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation- induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol. 2005;124(4):741-750.
41. van Doorn R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23(17):3886-3896.
42. Zhang C, Toulev A, Kamarashev J, Qin JZ, Dummer R, Dobbeling U. Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sezary syndrome and role of the bmi-1 and ras oncogenes in disease progression. Hum Pathol. 2007;38(7):995-1002. (Pubitemid 46899153)
43. Scarisbrick JJ, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. J Invest Dermatol. 2002;118(3):493-499. (Pubitemid 34227167)
44. Garrett-Engele CM, et al. A mechanism misregulating p27 in tumors discovered in a functional genomic screen. PLoS Genet. 2007;3(12):e219.
45. Bagui TK, et al. Inhibition of p27Kip1 gene transcription by mitogens. Cell Cycle. 2009;8(1):115-124.
46. Lim MS, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood. 2002;100(8):2950-2956.
47. Amati B, Vlach J. Kip1 meets SKP2: new links in cell-cycle control. Nat Cell Biol. 1999;1(4):E91-E93.
48. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1(4):193-199. (Pubitemid 129500937)
49. Xiang-Lan M, Zu-Lan S, Dan H, Bi-Hong S, Ya-Qin P, Han-Liang L. Skp2/p27 expression profile is correlated with Epstein-Barr virus status in extranodal nasal-type natural killer cell lymphoma. Transl Res. 2008;151(6):303-308. (Pubitemid 351736005)
50. Seki R, et al. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol. 2003;73(4):230-235. (Pubitemid 36898878)
51. Kang-Decker N, et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell. 2004;5(2):177-189. (Pubitemid 38283803)
52. Dehan E, Pagano M. Skp2, the FoxO1 hunter. Cancer Cell. 2005;7(3):209-210. (Pubitemid 40568679)
53. Huang H, et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A. 2005;102(5):1649-1654. (Pubitemid 40209222)
54. Chromy LR, Pipas JM, Garcea RL. Chaperone-mediated in vitro assembly of Polyomavirus capsids. Proc Natl Acad Sci U S A. 2003;100(18):10477-10482. (Pubitemid 37071903)
55. Mao X, et al. A genomic and expression study of AP- 1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol. 2008;35(10):899-910.
56. Wain EM, Mitchell TJ, Russell-Jones R, Whittaker SJ. Fine mapping of chromosome 10q deletions in mycosis fungoides and sezary syndrome: identification of two discrete regions of deletion at 10q23.33- 24.1 and 10q24.33-25.1. Genes Chromosomes Cancer. 2005;42(2):184-192. (Pubitemid 40094103)
57. Mao X, Lillington DM, Czepulkowski B, Russell- Jones R, Young BD, Whittaker S. Molecular cytogenetic characterization of Sezary syndrome. Genes Chromosomes Cancer. 2003;36(3):250-260. (Pubitemid 36158198)
58. Mao X, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol. 2002;147(3):464-475. (Pubitemid 35015279)
59. Fischer TC, et al. Genomic aberrations and survival in cutaneous T cell lymphomas. J Invest Dermatol. 2004;122(3):579-586. (Pubitemid 38471321)
60. Kim HS. Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet Cell Genet. 1999;84(1-2):93.
61. Vonderheid EC, Bernengo MG. The Sezary syndrome: hematologic criteria. Hematol Oncol Clin North Am. 2003;17(6):1367-1389.
62. Green DS, Center DM, Cruikshank WW. Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy. J Virol. 2009;83(11):5765-5772.
63. McFadden C, et al. Preferential migration of T regulatory cells induced by IL-16. J Immunol. 2007;179(10):6439-6445.
64. Center DM, et al. Measurement of interleukin 16. Curr Protoc Immunol. 2001;Chapter 6:Unit 6.23.